Recent research shows that although testicular cancer survivors do not totally conform to the criteria for metabolic syndrome, past treatment with platinum-based chemotherapy increases its prevalence among survivors and may lead to a greater risk for heart disease in this patient population.
Results from the ongoing Platinum Study revealed the prevalence of risk factors for CVD among survivors of testicular cancer who received chemotherapy for their cancer.
Survivors of testicular cancer are more likely to develop metabolic syndrome after platinum-based chemotherapy.
Patients without insurance and those with Medicaid have an increased risk of presenting with advanced testicular cancer and cancer-related death compared with those who have insurance.
Patients with stage IIA testicular cancer gain a survival advantage from treatment with radiation therapy compared with chemotherapy.
A new study has uncovered four new genetic variants associated with increased risk of testicular cancer. Testing for these and all 21 previously identified variants using genetic sequencing identified men at higher risk of testicular cancer.
Scientists have developed a test that assesses 3 features of nonseminomatous germ cell tumor, a common kind of testicular cancer, to identify those patients at greatest risk of relapse.
Recent study explored whether chronic fatigue is more prevalent in survivors of testicular cancer than the general population.
Patients with testicular nonseminoma have significantly increased cardiovascular disease mortality after chemotherapy.
Compared with the vasectomy and control groups, infertile men had a higher risk of testis cancer, non-Hodgkin lymphoma, and all cancers.
Taking muscle-building supplements significantly increases likelihood of developing testicular cancer.
Individuals who've had testicular cancer may be at increased risk for prostate cancer, but the overall risk is low, according to a study.
An increase in incidence of testicular germ cell tumors in Hispanic adolescents and young adults in the United States has been observed.
A new analysis has found that rates of testicular cancer have been rising dramatically in recent years among young Hispanic American men, but not among their non-Hispanic counterparts.
Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk for long-term side effects, according to a new study.
Four newly identified genetic variants are associated with an increased risk of testicular cancer, according to a new study that examined the genomes of over 13,000 men.
The incidence of testicular germ cell tumors (TGCT) increased from 1992 to 2009, especially among Hispanic men.
Immediate health risks supersede lifetime radiation-induced cancer risk in patients undergoing computed tomography surveillance for testicular cancer.
Risk highest for nonseminoma and mixed histology tumors.
A large UK study found a wide variation between cancer types in patients who had visited their general practitioner 3 or more times before cancer diagnosis.
Only a relatively small proportion of second cancers in adults is related to routine radiotherapy administered for initial disease, according to the findings of a recent study.
Adult men who were thought to be rendered sterile due to chemotherapy for childhood cancer may be able to reproduce with the help of a surgical technique that has recently been shown to locate and extract viable sperm.
Men who received a diagnosis of testicular cancer after age 40 years were twice as likely to die of the disease, according to the findings of a recent study.
Use of marijuana may increase the risk of testicular cancer, according to a study presented at the Annual Meeting of the American Association for Cancer Research.
A recent study finds that smoking cannabis increases a man's risk of developing testicular cancer
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|